Evidence map›Paper›PMID 38073378›Full record

ArticleCancer biomarkers : section A of Disease markers2023

A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer.

Yang Liu, Yan-Song Han, Jin-Feng Wang, Zhong-Qi Pang, Jian-She Wang, Lu Zhang, Jia-Xin He, Lin-Kun Shen, Bo Ji, Bei-Chen Ding and 1 more

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yang Liu
Yan-Song Han
Jin-Feng Wang
Zhong-Qi Pang
Jian-She Wang
Lu Zhang
Jia-Xin He
Lin-Kun Shen
Bo Ji
Bei-Chen Ding
Ming-Hua Ren

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe biological roles of immune-related genes (IRGs) in bladder cancer (BC) need to be further elucidated.

objectiveTo elucidate the predictive value of IRGs for prognosis and immune escape in BC.

methodsWe comprehensively analyzed the transcriptomic and clinical information of 430 cases, including 19 normal and 411 BC patients from the TCGA database, and verified 165 BC cases in the GSE13507 dataset. The risk model was constructed based on IRGs by applying LASSO Cox regression and exploring the relationship between the risk score and prognosis, gene mutations, and immune escape in BC patients.

resultsWe identified 4 survival-related genes (PSMC1, RAC3, ROBO2 and ITGB3) among 6,196 IRGs in both the TCGA and GES13507 datasets,, which were used to establish a gene risk model by applying LASSO Cox regression. The results showed that the high-risk (HR) group was closely associated with poor survival or advanced pathological stage of BC. Furthermore, the risk score was found to be an independent risk factor for prognosis of BC patients. In addition, high-risk individuals showed a greater prevalence of TP53 mutations lower CD8+ T-cell and NK cell infiltration, higher Treg cell infiltration, higher expression of PD-L1, and higher immune exclusion scores than those in the low-risk (LR) group. Finally, the experimental verification shows that the model construction gene, especially PMSC1, plays an important role in the growth and metastasis of bladder cancer.

conclusionsThese evidences revealed the vital role of IRGs in predicting prognosis, TP53 mutation and immune escape in BC patients.

Indexed as

Urinary Bladder NeoplasmsCD8-Positive T-LymphocytesDatabases, FactualGene Expression ProfilingHumansPrognosisBladder cancerimmune escapeprognosisrisk model

Identifiers

PMID38073378
PMCPMC12412879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.